Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
  - Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC…
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the…
Wi-Charge Adds CMO and VP of People to Executive Team Following Series C Funding
Strategic Hires Underscore Momentum as Company Expands Global Commercialization of Long-Range Wireless…
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Initial results from the First in Human (FIH) Phase 1 trial evaluating…
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co.,…
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366…
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO…
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET Â | Source: Scancell Holdings Plc SCOPE trial…